The American Journal of Managed Care > February 2020

The American Journal of Managed Care - February 2020

February 14, 2020 – Ekaterina Anderson, PhD; Renda Soylemez Wiener, MD, MPH; Kirsten Resnick, MS; A. Rani Elwy, PhD; and Seppo T. Rinne, MD, PhD
Improving relational coordination and reducing structural barriers to collaboration may enhance quality of care for chronic obstructive pulmonary disease (COPD) and other chronic conditions.
February 13, 2020 – A. Mark Fendrick, MD
Innovative, cost-neutral plan designs that cover more essential services on a predeductible basis, while decreasing exposure to and spending on harmful care, would better meet the clinical and financial needs of millions of Americans.
February 14, 2020 – Jeffrey D. Dunn, PharmD, MBA
February 12, 2020 – Interview by Allison Inserro
To mark the 25th anniversary of the journal, each issue in 2020 will include an interview with a healthcare thought leader. For the February issue, we turned to Gail Wilensky, PhD, an economist and senior fellow at Project HOPE.
February 13, 2020 – Lisa M. Lines, PhD, MPH; Wayne L. Anderson, PhD; Harper Gordek, MPH; and Anne E. Kenyon, MBA
The authors disagree with previous research concluding that the Home Health Care Consumer Assessment of Healthcare Providers and Services (CAHPS) publicly reported data are insufficiently adjusted for patient comorbidities.
February 13, 2020 – Hsueh-Fen Chen, PhD; J. Mick Tilford, PhD; Robert F. Schuldt, MA; and Fei Wan, PhD
The authors of “CMS HCC Risk Scores and Home Health Patient Experience Measures” respond to a letter to the editor.
February 12, 2020 – Melissa B. Gilkey, PhD; Lauren A. Cripps, MA; Rachel S. Gruver, MPH; Deidre V. Washington, PhD; and Alison A. Galbraith, MD, MPH
Findings of this qualitative interview study suggest promise, but also challenges, with regard to using preventive drug lists to help families manage asthma medication costs.
February 14, 2020 – Lindsay M. Sabik, PhD; Anushree M. Vichare, PhD; Bassam Dahman, PhD; and Cathy J. Bradley, PhD
Co-payments for preventive services can discourage breast and cervical cancer screening among Medicaid enrollees, particularly breast cancer screening, which is more costly and time-consuming.
February 12, 2020 – Jeah Jung, PhD, MPH; Ping Du, MD, PhD; Roger Feldman, PhD; and Thomas Riley III, MD
Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.
February 05, 2020 – Arti Parikh-Patel, PhD, MPH; Cyllene R. Morris, DVM, PhD; Frances B. Maguire, PhD, MPH; Megan E. Daly, MD; and Kenneth W. Kizer, MD, MPH
This population-based analysis of patients with cancer in California found significant differences in proton beam therapy use by health insurance type, race/ethnicity, and socioeconomic status.
February 07, 2020 – Amber Watson, PharmD; David M. Simon, PhD; Meridith Blevins Peratikos, MS; and Elizabeth Ann Stringer, PhD
Medical utilization profiles of commercially insured members with opioid-related disorders differ depending on the code used to document the initial diagnosis in administrative claims.
February 10, 2020 – Brian W. Powers, MD, MBA; Farhad Modarai, DO; Sandeep Palakodeti, MD, MPH; Manisha Sharma, MD; Nupur Mehta, MD; Sachin H. Jain, MD, MBA; and Vivek Garg, MD, MBA
Complex care management for high-need, high-cost Medicaid patients significantly reduced total medical expenditures and inpatient utilization in a randomized quality improvement trial.
February 10, 2020 – Jesse Sussell, PhD; Emma van Eijndhoven, MS, MA; Taylor T. Schwartz, MPH; Suzanne J. Baron, MD, MSc; Christin Thompson, PhD; Seth Clancy, MPH; and Anupam B. Jena, MD, PhD
Transcatheter aortic valve replacement for inoperable severe, symptomatic aortic stenosis will create significant social value in the next decade, mostly accruing to patients versus manufacturers.
February 11, 2020 – Tatyana Feldman, MD; Denise Zou, MA; Mayvis Rebeira, PhD; Joseph Lee, PhD; Michelle Fanale, MD; Thomas Manley, MD; Shangbang Rao, PhD; Joseph Feliciano, PharmD; Mack Harris, BA; and Anuraag Kansal, PhD
An economic model based on the ECHELON-2 trial demonstrated cost-effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
February 11, 2020 – Tricia Johnson, PhD; Surrey Walton, PhD; Stacie Levine, MD; Erik Fister, MA; Aliza Baron, MA; and Sean O’Mahony, MB, BCh, BAO
Race/ethnicity was not a predictor of inpatient palliative care consultation or discharge to hospice in 4 hospitals with an inpatient palliative care service.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.